Clarithromycin, tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection

M. T. Al-Assi, Francisco C Ramirez, G. M. Lew, R. M. Genta, D. Y. Graham

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: Metronidazole resistance has become an increasing problem that has limited the usefulness of the original triple therapy. Our objective was to evaluate clarithromycin, a new macrolide compound active against Helicobacter pylori. Methods: We evaluated a new clarithromycin triple therapy for H. pylori infection consisting of the combination of clarithromycin (500 mg t.i.d.), tetracycline (500 mg q.i.d.), and bismuth subsalicylate tablets (2 q.i.d.) for 14 days. Patients with ulcer also received concomitant ranitidine, 300 mg after the evening meal, for 6 wk. Results: Thirty men with documented H. pylori infection were studied; 29 had peptic ulcer disease. Seven had previously failed antimicrobial therapy, including three with metronidazole-based triple therapy. H. pylori status was determined by histology. H. pylori status and ulcer status were evaluated 4 wk after the end of antimicrobial therapy. The ulcer was healed in 90%. The H. pylori infection was cured in 93%, including all three patients who previously failed metronidazole-based triple therapy. Conclusion: We conclude that the combination of clarithromycin, tetracycline, and bismuth is an effective new therapy for treatment of H. pylori infection.

Original languageEnglish (US)
Pages (from-to)1203-1205
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume89
Issue number8
StatePublished - 1994
Externally publishedYes

Fingerprint

Bismuth
Clarithromycin
Helicobacter Infections
Tetracycline
Helicobacter pylori
Metronidazole
Ulcer
Therapeutics
Ranitidine
Macrolides
Peptic Ulcer
Tablets
Meals
Histology

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clarithromycin, tetracycline, and bismuth : A new non-metronidazole therapy for Helicobacter pylori infection. / Al-Assi, M. T.; Ramirez, Francisco C; Lew, G. M.; Genta, R. M.; Graham, D. Y.

In: American Journal of Gastroenterology, Vol. 89, No. 8, 1994, p. 1203-1205.

Research output: Contribution to journalArticle

@article{43cbd7b3179044efb684eb2b7db77801,
title = "Clarithromycin, tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection",
abstract = "Objective: Metronidazole resistance has become an increasing problem that has limited the usefulness of the original triple therapy. Our objective was to evaluate clarithromycin, a new macrolide compound active against Helicobacter pylori. Methods: We evaluated a new clarithromycin triple therapy for H. pylori infection consisting of the combination of clarithromycin (500 mg t.i.d.), tetracycline (500 mg q.i.d.), and bismuth subsalicylate tablets (2 q.i.d.) for 14 days. Patients with ulcer also received concomitant ranitidine, 300 mg after the evening meal, for 6 wk. Results: Thirty men with documented H. pylori infection were studied; 29 had peptic ulcer disease. Seven had previously failed antimicrobial therapy, including three with metronidazole-based triple therapy. H. pylori status was determined by histology. H. pylori status and ulcer status were evaluated 4 wk after the end of antimicrobial therapy. The ulcer was healed in 90{\%}. The H. pylori infection was cured in 93{\%}, including all three patients who previously failed metronidazole-based triple therapy. Conclusion: We conclude that the combination of clarithromycin, tetracycline, and bismuth is an effective new therapy for treatment of H. pylori infection.",
author = "Al-Assi, {M. T.} and Ramirez, {Francisco C} and Lew, {G. M.} and Genta, {R. M.} and Graham, {D. Y.}",
year = "1994",
language = "English (US)",
volume = "89",
pages = "1203--1205",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Clarithromycin, tetracycline, and bismuth

T2 - A new non-metronidazole therapy for Helicobacter pylori infection

AU - Al-Assi, M. T.

AU - Ramirez, Francisco C

AU - Lew, G. M.

AU - Genta, R. M.

AU - Graham, D. Y.

PY - 1994

Y1 - 1994

N2 - Objective: Metronidazole resistance has become an increasing problem that has limited the usefulness of the original triple therapy. Our objective was to evaluate clarithromycin, a new macrolide compound active against Helicobacter pylori. Methods: We evaluated a new clarithromycin triple therapy for H. pylori infection consisting of the combination of clarithromycin (500 mg t.i.d.), tetracycline (500 mg q.i.d.), and bismuth subsalicylate tablets (2 q.i.d.) for 14 days. Patients with ulcer also received concomitant ranitidine, 300 mg after the evening meal, for 6 wk. Results: Thirty men with documented H. pylori infection were studied; 29 had peptic ulcer disease. Seven had previously failed antimicrobial therapy, including three with metronidazole-based triple therapy. H. pylori status was determined by histology. H. pylori status and ulcer status were evaluated 4 wk after the end of antimicrobial therapy. The ulcer was healed in 90%. The H. pylori infection was cured in 93%, including all three patients who previously failed metronidazole-based triple therapy. Conclusion: We conclude that the combination of clarithromycin, tetracycline, and bismuth is an effective new therapy for treatment of H. pylori infection.

AB - Objective: Metronidazole resistance has become an increasing problem that has limited the usefulness of the original triple therapy. Our objective was to evaluate clarithromycin, a new macrolide compound active against Helicobacter pylori. Methods: We evaluated a new clarithromycin triple therapy for H. pylori infection consisting of the combination of clarithromycin (500 mg t.i.d.), tetracycline (500 mg q.i.d.), and bismuth subsalicylate tablets (2 q.i.d.) for 14 days. Patients with ulcer also received concomitant ranitidine, 300 mg after the evening meal, for 6 wk. Results: Thirty men with documented H. pylori infection were studied; 29 had peptic ulcer disease. Seven had previously failed antimicrobial therapy, including three with metronidazole-based triple therapy. H. pylori status was determined by histology. H. pylori status and ulcer status were evaluated 4 wk after the end of antimicrobial therapy. The ulcer was healed in 90%. The H. pylori infection was cured in 93%, including all three patients who previously failed metronidazole-based triple therapy. Conclusion: We conclude that the combination of clarithromycin, tetracycline, and bismuth is an effective new therapy for treatment of H. pylori infection.

UR - http://www.scopus.com/inward/record.url?scp=0028074524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028074524&partnerID=8YFLogxK

M3 - Article

C2 - 8053435

AN - SCOPUS:0028074524

VL - 89

SP - 1203

EP - 1205

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -